FOLH1 and neoplasm: Another approach for PSMA-specific targeting is based on engineered T cells expressing chimeric anti-PSMA immunoglobulin-T-cell-receptor constructs which were shown to specifically lyse PSMA-expressing PCa cells and retard tumor growth in a mouse xenograft model [64].